PFE Stock Recent News Pfizer Inc (PFE) 30.34 11/14/2014 18:3

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Pfizer Inc (PFE) 30.34 $PFE

Final Glance: Pharmaceuticals companies
AP - 1 hr 28 mins ago
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)

Zoetis adopts shareholder rights plan
By The Associated Press - AP - 1 hr 45 mins ago
Zoetis Inc. said Friday that it has adopted a one-year shareholder rights plan.
ZTS: 43.14 (-0.10), PFE: 30.34 (-0.08)

Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)

Early Glance: Pharmaceuticals companies
AP - Fri Nov 14, 9:47AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
JNJ: 108.16 (-0.91), BAX: 71.75 (-0.33), PFE: 30.34 (-0.08), BMY: 57.95 (+0.15)

Is Johnson & Johnson A Stock Worth Having In The Portfolio Right Now?
Abba's Aces - at Seeking Alpha - Fri Nov 14, 1:36AM CST

JNJ: 108.16 (-0.91), PFE: 30.34 (-0.08), ABBV: 64.00 (+0.37)

Most active New York Stock Exchange-traded stocks
AP - Thu Nov 13, 5:05PM CST
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
KMI: 39.37 (+0.99), ZTS: 43.14 (-0.10), GE: 26.46 (+0.04), F: 15.14 (+0.21), S: 5.05 (+0.05), PFE: 30.34 (-0.08), JCP: 7.38 (+0.28), HAL: 55.08 (+1.29), WMT: 82.96 (+0.02), BAC: 17.14 (-0.08), TWTR: 41.85 (+1.81), GNW: 9.41 (+0.11)

Ad Comm meeting approaches to discuss risks of epidural steroid injections
Seeking Alpha - at Seeking Alpha - Thu Nov 13, 10:56AM CST

PFE: 30.34 (-0.08), MRK: 59.07 (-0.47), BMY: 57.95 (+0.15), NVS: 93.95 (-0.43)

Novel Agreement Expands Access to Pfizer's Contraceptive, Sayana(R) Press, for Women Most in Need in the World's Poorest Countries
Business Wire - Thu Nov 13, 10:00AM CST
Pfizer Inc., the Bill & Melinda Gates Foundation and the Children's Investment Fund Foundation (CIFF) today announced an agreement that will expand access to Pfizer's injectable contraceptive, Sayana(R) Press (medroxyprogesterone acetate), for women most in need in 69 of the world's poorest countriesi. Through this collaboration of organizations from the public and private sectors, Sayana(R) Press will be sold for US $1 per dose to qualified purchasers, who can help enable the poorest women in these countries to have access to the contraceptive at reduced or no cost.
PFE: 30.34 (-0.08)

BIND Therapeutics Offers Great Potential With Upcoming Catalyst
Long Term Bio - at Seeking Alpha - Thu Nov 13, 8:10AM CST

PFE: 30.34 (-0.08), MRK: 59.07 (-0.47), AZN: 72.85 (-1.68), BIND: 10.26 (+0.35)

Testosterone Sales Slump as Testosterone Lawsuit MDL Builds Momentum, Report Attorneys Handling National Testosterone Lawsuits
PRWeb - Thu Nov 13, 2:22AM CST
Lawyers providing legal representation for testosterone lawsuits report progress in the national multidistrict litigation for testosterone lawsuits; meanwhile, a major news source, Bloomberg Businessweek, reported on losses in the testosterone replacement therapy market. These attorneys offer timely testosterone lawsuit news updates and testosterone lawsuit case review at androgeltestosteronelawsuitcenter.com.
PFE: 30.34 (-0.08), ABBV: 64.00 (+0.37)

Pfizer's (PFE) Management Presents at Credit Suisse 2014 Healthcare Conference Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 12, 3:25PM CST

PFE: 30.34 (-0.08)

Pandering Your Wealth Away
Morgan Housel, The Motley Fool - Motley Fool - Wed Nov 12, 12:44PM CST
"My job is to write the exact same thing between 50 and 100 times a year in such a way that neither my editors nor my readers will ever think I am repeating myself," Wall Street Journal columnist Jason Zweig once wrote.  The reason, he said, is...
JNJ: 108.16 (-0.91), PFE: 30.34 (-0.08), MRK: 59.07 (-0.47), AMGN: 157.68 (-3.17), MO: 48.78 (-0.67), CVX: 116.32 (-0.13)

Ackman and a Former Protege Launch Campaign at Zoetis
at The Street - Wed Nov 12, 10:49AM CST
Investors will look for response from Zoetis on its investor day scheduled for Nov. 18.
ZTS: 43.14 (-0.10), PFE: 30.34 (-0.08)

Today's Market: Mergers, Rumors And Earnings Moving These Stocks
Matthew Smith - at Seeking Alpha - Wed Nov 12, 10:04AM CST

ZTS: 43.14 (-0.10), T: 35.90 (+0.29), VRX: 134.21 (+2.31), FOSL: 108.32 (-1.49), BBT: 37.43 (-0.15), PFE: 30.34 (-0.08), KORS: 72.06 (+1.32), SUSQ: 13.15 (+0.09)

Bill Ackman's Latest Target: Zoetis Inc.
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 12, 9:40AM CST
Source: Zoetis. Pershing Square's Bill Ackman is probably best known for his relentless advocacy regarding his short position in Herbalife , but he's also captured a lot of attention this year as being a key voice of support for the sale of ...
ZTS: 43.14 (-0.10), AGN: 198.65 (+2.44), HLF: 38.50 (+0.65), VRX: 134.21 (+2.31), PFE: 30.34 (-0.08), MRK: 59.07 (-0.47), LLY: 67.33 (-0.35)

5 Things Actavis plc's Management Wants You to Know
George Budwell, The Motley Fool - Motley Fool - Wed Nov 12, 8:21AM CST
The pharmaceutical industry has had a banner year in many ways, fueled by a slew of major drug approvals in recent years, numerous mergers and acquisitions, and significant corporate reorganizations that have helped to boost earnings. The specialty...
DRTX: 23.75 (unch), AGN: 198.65 (+2.44), ACT: 243.77 (+2.14), IRWD: 13.13 (-0.36), CBST: 70.52 (-1.22), PFE: 30.34 (-0.08)

Warren Buffett's Investing Strategy: Is Pfizer Inc. a Perfect Fit?
Sean Williams, The Motley Fool - Motley Fool - Wed Nov 12, 7:03AM CST
Here at The Motley Fool, we sing the praises of Warren Buffett quite often -- and with good reason. Buffett, in a hair over 60 years, turned a small fortune of around $10,000 into a net worth of more than $70 billion as of this past Friday. Clearly,...
PFE: 30.34 (-0.08)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cardiovalve's Three-Year Data Clears a Crucial EU Hurdle

Updated Category News Views 110

A failing tricuspid valve is not a spreadsheet problem, and that matters before anybody gets carried away with a glossy conference presentation. Venus Medtech's Cardiovalve unit has reported results from TARGET in a population that was old, sick and largely out of good surgical options. That is precisely where a less invasive replacement therapy has to prove it can do...

Continue Reading
UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 394

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 570

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Anthropic Bears Get New Tools, But Daily Risk Bites

Updated Category News Views 64

A $81.3 Billion Offering Invites Fast Money Anthropic arrived in public markets with the sort of numbers that make traders reach for both a calculator and a helmet. The company priced 980 million Class A shares at $83 on November 18, 2026, raising roughly $81.3 billion, then opened at $111.50 when it began Nasdaq trading on November 19. That is a monster debut by any...

Continue Reading
CARsgen's CT1182 Data Opens a Careful New CAR-T Test

Updated Category News Views 140

Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...

Continue Reading
Global Child Tests Purpose Travel's Expanding Media Reach

Updated Category News Views 45

Celebrity travel programming usually melts into the wallpaper, but Global Child is trying to make the scenery answer for itself. Its new season of Global Child “Travel & Purpose” puts Andrea Bocelli in Tuscany, Isabela Merced in Peru and John Malkovich in Croatia, while tying each destination to a broader local-good mission. That is a more thoughtful pitch than...

Continue Reading
Australia Leads TTW's 2027 Global Travel Country List

Updated Category News Views 43

A travel ranking is a map, not a balance sheet, and that distinction matters more than the glossy numbering. TTW has put Australia at the head of its editorial list of the 50 best countries to visit in 2027, followed by Switzerland, Japan, Canada and Thailand. Fair enough. Those are formidable tourism brands with the scenery, infrastructure and cultural pull to back up...

Continue Reading
Build-A-Bear Lawsuit Notice Carries a Date Problem

Updated Category News Views 69

Something is badly out of sequence in the Build-A-Bear shareholder alert, and that matters before anybody gets carried away by the legal boilerplate. The notice says investors who bought NYSE: BBW securities from March 28, 2026 through August 26, 2026 may be covered by a proposed federal securities class action. It also says the lead-plaintiff deadline is January 19,...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 459

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
UAE Ties Diplomacy, Media and AI Into a Shared Signal

Updated Category News Views 128

Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...

Continue Reading

Top 5 Most Recently Viewed Articles

3Srobotics Breaks Ground with North American Debut

Updated Category News Views 204

3Srobotics Steps Into the Big League The sweltering buzz of FABTECH 2026 in Las Vegas signals more than just another industry tradeshow; it's the stage upon which 3Srobotics made its North American debut. In a span shorter than it takes most companies to get serious about their business cards, 3Srobotics has already nailed three funding rounds, snagging tens of millions...

Continue Reading
Uganda Plans Major Spending Cuts and Reduced Borrowing for 2025

Updated Category News Views 912

Uganda's government announced a hefty shift in its fiscal playbook back in 2024, aiming to cut spending by over 20% and slash domestic borrowing by more than half for the upcoming 2025/26 fiscal year. This wasn’t just some routine budgetary tweak; it was a necessary maneuver amidst growing alarm about the nation's spiraling public debt. You know these moves grab...

Continue Reading
Vivos Therapeutics to Share Q1 2025 Results and Updates Soon

Updated Category News Views 257

Vivos Therapeutics Prepares for Q1 2025 Financial Disclosure Vivos Therapeutics, Inc. (NASDAQ: VVOS), a pioneering company in the medical devices sector, is gearing up to release its financial results for the first quarter of 2025. This announcement is anticipated to take place following the market's closure on a Thursday in May 2025. The management team is set to hold a...

Continue Reading
Join XBP Global for the Annual Turkey Trot This Thanksgiving

Updated Category News Views 217

XBP Global Welcomes You to the 11th Annual Turkey Trot XBP Global Holdings, Inc. (NASDAQ: XBP) is thrilled to invite the community to the 11th Annual Palisades Turkey Trot, a cherished tradition returning this Thanksgiving morning. Held at Palisades Green, this year's event promises excitement with new 5K and 10K courses that enhance the festive atmosphere of the...

Continue Reading
Market Reaction to CEO Departure and Boot Barn's Strong Quarter

Updated Category News Views 317

Boot Barn Stock Forecast Amid CEO Transition and Solid Performance In the latest developments regarding Boot Barn (NYSE: BOOT), analysts at Craig-Hallum have made notable adjustments to their stock price outlook. The price target has been revised to $160 from a previous $162, maintaining a Hold rating. The adjustments come in light of the company's impressive performance...

Continue Reading